← Evidence map

ArticleCancers2026

Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE.

Roberta Massobrio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE. | OpenQuestion